Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $3.25 and last traded at $3.19, with a volume of 27533 shares. The stock had previously closed at $2.96.
A number of analysts recently issued reports on the company. HC Wainwright set a $5.00 target price on BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Monday. Cantor Fitzgerald reaffirmed a “buy” rating and set a $4.50 price target on shares of BioDelivery Sciences International in a research report on Thursday, August 9th. Finally, Zacks Investment Research raised BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research report on Monday, July 23rd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. BioDelivery Sciences International presently has a consensus rating of “Buy” and an average target price of $4.38.
The company has a debt-to-equity ratio of 1.21, a current ratio of 3.16 and a quick ratio of 2.90. The stock has a market capitalization of $166.77 million, a price-to-earnings ratio of -7.94 and a beta of 0.63.
BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings results on Thursday, August 9th. The specialty pharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. BioDelivery Sciences International had a negative return on equity of 278.79% and a negative net margin of 103.01%. The firm had revenue of $12.18 million during the quarter, compared to the consensus estimate of $12.44 million. As a group, equities research analysts predict that BioDelivery Sciences International, Inc. will post -0.62 earnings per share for the current year.
In other BioDelivery Sciences International news, Director Francis E. Odonnell, Jr. sold 151,039 shares of the company’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $2.84, for a total transaction of $428,950.76. Following the completion of the transaction, the director now owns 520,482 shares of the company’s stock, valued at approximately $1,478,168.88. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders have sold 167,039 shares of company stock valued at $473,271. Insiders own 13.26% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Bank of Montreal Can acquired a new stake in shares of BioDelivery Sciences International in the 2nd quarter valued at approximately $138,000. PNC Financial Services Group Inc. acquired a new stake in shares of BioDelivery Sciences International in the 2nd quarter valued at approximately $148,000. Foresite Capital Management III LLC acquired a new stake in shares of BioDelivery Sciences International in the 1st quarter valued at approximately $338,000. Renaissance Technologies LLC boosted its holdings in shares of BioDelivery Sciences International by 214.7% in the 2nd quarter. Renaissance Technologies LLC now owns 166,779 shares of the specialty pharmaceutical company’s stock valued at $492,000 after buying an additional 113,779 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of BioDelivery Sciences International by 19.9% in the 2nd quarter. Northern Trust Corp now owns 191,016 shares of the specialty pharmaceutical company’s stock valued at $563,000 after buying an additional 31,749 shares during the last quarter. 45.46% of the stock is owned by hedge funds and other institutional investors.
About BioDelivery Sciences International (NASDAQ:BDSI)
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Featured Article: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.